4D PHARMA ORD 0.25P overview

4D pharma plc (AIM: DDDD, NASDAQ: LBPS) , a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that in Part B of its signal finding study of MRx0518 in combination with MSD’s anti-PD-1 therapy, KEYTRUDA ® (pembrolizumab) in patients with solid tumors that have progressed on a prior immune checkpoint inhibitor (ICI), the renal cell carcinoma (RCC) group has met its primary efficacy endpoint...

Clinical Update - 4D Announce New Study of MRx0518 in Pancreatic Cancer 4D Pharma Announces Opening of a Study Investigating MRx0518 in Combination with Radiotherapy in Patients with Resectable Pancreatic Cancer PR Newswire LEEDS, England, Jan. 6, 2020 LEEDS, England , Jan. 6, 2020 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the opening of a clinical study to evaluate the safety and preliminary clinical...

4D pharma plc: Oncology Programmes Update Second-generation Live Biotherapeutic Identified and Mechanistic Data on MRx0518 and MRx1299 Presented PR Newswire LEEDS, England, July 25, 2019 LEEDS, England , July 25, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on its oncology programmes. New preclinical data on the Company's oncology candidates, MRx0518 and MRx1299, were presented at 1 st...

4D Pharma Clinical Update - MRx0518 Oncology Programmes PR Newswire LEEDS, England, April 29, 2019 LEEDS, England , April 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces an update on the clinical progress of its lead oncology Live Biotherapeutic MRx0518. Update on MRx0518 Phase I/II combination study with KEYTRUDA ® (pembrolizumab) The first patient participating in the combination phase I/II study of...

4D Pharma Announces Publication of Data Highlighting Immuno-Stimulatory Properties of MRx0518 PR Newswire LEEDS, England, January 29, 2019 LEEDS, England , January 29, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the publication of a paper outlining the mechanism and strong immuno-stimulatory effects of MRx0518. The paper ' The flagellin of candidate live biotherapeutic Enterococcus gallinarum MRx0518 is...

4D pharma plc: Appointment of Independent Non-Executive Directors PR Newswire LEEDS, England, January 8, 2019 LEEDS, England , January 8, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutics, today announces the appointment of Ed Baracchini , PhD, and Professor Axel Glasmacher , MD, as independent Non-Executive Directors with immediate effect. Ed Baracchini , PhD, was previously the Chief Business Officer at Xencor Inc. where he...

4D pharma and MD Anderson Cancer Center to Evaluate Live Biotherapeutics in Solid Tumours PR Newswire LEEDS, England and HOUSTON, January 7, 2019 LEEDS, England and HOUSTON , January 7, 2019 /PRNewswire/ -- 4D pharma plc (AIM: DDDD) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to evaluate 4D's Live Biotherapeutic oncology pipeline across a range of cancer settings. The alliance brings together MD Anderson's translational medicine and clinical...

4D Presents at IHMC 2018 PR Newswire LEEDS, England, June 27, 2018 LEEDS, England , June 27, 2018 /PRNewswire/ -- 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of live biotherapeutics, today announced that the Company's Chief Scientific Officer, Dr. Alex Stevenson , has spoken at the International Human Microbiome Consortium (IHMC) 2018 on the importance of function in the development of live biotherapeutics. "Ahead of World Microbiome Day, IHMC 2018 is an important...